Taysha Gene Therapies PE Ratio 2020-2024 | TSHA
Current and historical p/e ratio for Taysha Gene Therapies (TSHA) from 2020 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Taysha Gene Therapies PE ratio as of November 20, 2024 is 30.29.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Taysha Gene Therapies PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2024-11-19 |
2.12 |
|
2.90 |
| 2024-09-30 |
2.01 |
$0.73 |
2.75 |
| 2024-06-30 |
2.24 |
$-0.20 |
0.00 |
| 2024-03-31 |
2.87 |
$-0.49 |
0.00 |
| 2023-12-31 |
1.77 |
$-0.67 |
0.00 |
| 2023-09-30 |
3.16 |
$-2.58 |
0.00 |
| 2023-06-30 |
0.66 |
$-2.29 |
0.00 |
| 2023-03-31 |
0.80 |
$-2.75 |
0.00 |
| 2022-12-31 |
2.26 |
$-3.78 |
0.00 |
| 2022-09-30 |
1.93 |
$-4.11 |
0.00 |
| 2022-06-30 |
3.72 |
$-4.82 |
0.00 |
| 2022-03-31 |
6.52 |
$-5.07 |
0.00 |
| 2021-12-31 |
11.65 |
$-4.63 |
0.00 |
| 2021-09-30 |
18.62 |
$-3.31 |
0.00 |
| 2021-06-30 |
21.20 |
$-3.24 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.434B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
